平消片联合索拉非尼治疗中晚期原发性肝癌的临床研究
|
摘要
目的探究平消片联合甲苯磺酸索拉非尼片治疗中晚期原发性肝癌的临床疗效。方法选取2016年1月—2017年8月在南阳市中心医院接受规范治疗的中晚期原发性肝癌患者116例为研究对象,将入选患者按抗肿瘤方案分为对照组和治疗组,每组各58例。对照组口服甲苯磺酸索拉非尼片,400 mg/次,2次/d。治疗组在对照组治疗的基础上口服平消片,0.92g/次,3次/d。两组患者均连续治疗12周。观察两组的临床疗效,比较两组的生活质量、癌痛程度、肿瘤标志物和生存情况。结果治疗后,对照组和治疗组的临床获益率分别为70.69%、84.48%,客观缓解率分别为25.86%、51.72%,两组比较差异有统计学意义(P<0.05)。治疗后,两组KPS评分、SF-36评分均高于治疗前,VAS评分均低于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组KPS评分、SF-36评分高于对照组,VAS评分低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清AFP水平均明显低于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组血清AFP水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组中位生存期明显长于对照组,1年存活率显著高于对照组,两组比较差异有统计学意义(P<0.05)。结论平消片联合甲苯磺酸索拉非尼片治疗中晚期原发性肝癌具有较好的临床疗效,能改善患者生活质量、生存情况,具有一定临床推广应用价值。
Objective To observe the effect of Pingxiao Tablets combined with Sorafenib Tosylate Tablets in treatment of middleadvanced primary liver cancer. Methods Patients(116 cases) with middle-advanced primary liver cancer in Nanyang Central Hospital from January 2016 to August 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Pingxiao Tablets on the basis of the control group, 0.3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and quality of life, cancer pain degree, tumor markers, and survival situations in two groups were compared. Results After treatment, the clinical benefit rates in the control and treatment groups were 70.69% and 84.48%, respectively, and the objective response rates in the control and treatment groups were 25.86% and 51.72%, respectively, and there was difference between two groups(P < 0.05). After treatment, KPS scores and SF-36 scores in two groups were significantly increased, but VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of AFP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the levels of AFP in the treatment group was significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the median survival time in the treatment group was significantly longer than that in the control group, and the 1-year survival rate in the treatment group was significantly higher than that in the control group, and there was difference between two groups(P < 0.05). Conclusion Pingxiao Tablets combined with Sorafenib Tosylate Tablets has clinical curative effect in treatment of middle-advanced primary liver cancer, can improve quality of life and survival situation, which has a certain clinical application value.
Objective To observe the effect of Pingxiao Tablets combined with Sorafenib Tosylate Tablets in treatment of middleadvanced primary liver cancer. Methods Patients(116 cases) with middle-advanced primary liver cancer in Nanyang Central Hospital from January 2016 to August 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Pingxiao Tablets on the basis of the control group, 0.3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and quality of life, cancer pain degree, tumor markers, and survival situations in two groups were compared. Results After treatment, the clinical benefit rates in the control and treatment groups were 70.69% and 84.48%, respectively, and the objective response rates in the control and treatment groups were 25.86% and 51.72%, respectively, and there was difference between two groups(P < 0.05). After treatment, KPS scores and SF-36 scores in two groups were significantly increased, but VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of AFP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the levels of AFP in the treatment group was significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the median survival time in the treatment group was significantly longer than that in the control group, and the 1-year survival rate in the treatment group was significantly higher than that in the control group, and there was difference between two groups(P < 0.05). Conclusion Pingxiao Tablets combined with Sorafenib Tosylate Tablets has clinical curative effect in treatment of middle-advanced primary liver cancer, can improve quality of life and survival situation, which has a certain clinical application value.
引文
[1]魏天翼,顾殿华,时汀,等.索拉非尼在肝细胞性肝癌患者临床治疗中的应用效果[J].实用癌症杂志,2016,31(5):846-848.
[2]戴峰,朱西琪.索拉非尼在中晚期肝细胞肝癌治疗中的临床价值[J].东南大学学报:医学版,2016,35(1):106-108..
[3]孟亚平.索拉非尼联合TACE治疗进展期原发性肝癌的临床研究[J].肝脏,2016,21(10):867-870.
[4]刘林森,龙文汀,张悦,等.索拉非尼对肝癌细胞中PD-L1表达的影响及机制[J].山东医药,2017,57(29):5-7.
[5]孙秋实,曹传华,张凌云.平消胶囊联合肝动脉栓塞化疗治疗中晚期肝癌60例的临床分析[J].现代肿瘤医学,2012,20(2):322-324.
[6]慕竹青,韩丽娟.复方苦参注射液联合平消片对乳腺癌患者血清相关因子及T淋巴细胞亚群的影响[J].中国合理用药探索,2017,14(11):17-19.
[7]Edge S B,Compton C C.The american joint committee on cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471-1474.
[8]Mor V,Laliberte L,Morris J N,et al.The karnofsky performance status scale:an examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[9]李鲁,王红妹,沈毅.SF-36健康调查量表中文版的研制及其性能测试[J].中华预防医学杂志,2002,36(2):109-113.
[10]Collins S L,Moore R A,McQuay H J.The visual analogue pain intensity scale:what is moderate pain in millimetres[J].Pain,1997,72(1-2):95-97.
[11]Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid tumours-revised RECISTguideline(version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[12]吴友祥,路远,晏彬,等.血清白细胞介素-35水平对索拉菲尼联合非规则性肝切除术治疗的原发性肝癌患者临床疗效及预后的影响[J].广西医学,2017,39(6):782-785.
[13]王程,王宁菊.索拉菲尼治疗晚期原发性肝癌患者的临床疗效及毒副反应观察[J].宁夏医学杂志,2015,37(12):1139-1140.
[14]张惠洁,郭卫东,屈振杰.TACE联合索拉菲尼治疗原发性肝癌的疗效观察及血清VEGF、bFGF水平的变化[J].现代肿瘤医学,2015,23(21):3164-3168.
[15]杨军英,程体娟,马建秀.平消片对荷瘤小鼠免疫功能的影响[J].中药药理与临床,2001,17(2):32-33.
[16]肖晓红,姜立伟,张荣华,等.平消片联合化疗治疗中晚期原发性肝癌的临床疗效观察[J].肿瘤药学,2012,2(3):216-219.
[17]甘雨,于新发,周成宇,等.甲胎蛋白在原发性肝癌的诊断和预后判断中的临床价值[J].海南医学,2016,27(6):891-894.
[2]戴峰,朱西琪.索拉非尼在中晚期肝细胞肝癌治疗中的临床价值[J].东南大学学报:医学版,2016,35(1):106-108..
[3]孟亚平.索拉非尼联合TACE治疗进展期原发性肝癌的临床研究[J].肝脏,2016,21(10):867-870.
[4]刘林森,龙文汀,张悦,等.索拉非尼对肝癌细胞中PD-L1表达的影响及机制[J].山东医药,2017,57(29):5-7.
[5]孙秋实,曹传华,张凌云.平消胶囊联合肝动脉栓塞化疗治疗中晚期肝癌60例的临床分析[J].现代肿瘤医学,2012,20(2):322-324.
[6]慕竹青,韩丽娟.复方苦参注射液联合平消片对乳腺癌患者血清相关因子及T淋巴细胞亚群的影响[J].中国合理用药探索,2017,14(11):17-19.
[7]Edge S B,Compton C C.The american joint committee on cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471-1474.
[8]Mor V,Laliberte L,Morris J N,et al.The karnofsky performance status scale:an examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[9]李鲁,王红妹,沈毅.SF-36健康调查量表中文版的研制及其性能测试[J].中华预防医学杂志,2002,36(2):109-113.
[10]Collins S L,Moore R A,McQuay H J.The visual analogue pain intensity scale:what is moderate pain in millimetres[J].Pain,1997,72(1-2):95-97.
[11]Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid tumours-revised RECISTguideline(version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[12]吴友祥,路远,晏彬,等.血清白细胞介素-35水平对索拉菲尼联合非规则性肝切除术治疗的原发性肝癌患者临床疗效及预后的影响[J].广西医学,2017,39(6):782-785.
[13]王程,王宁菊.索拉菲尼治疗晚期原发性肝癌患者的临床疗效及毒副反应观察[J].宁夏医学杂志,2015,37(12):1139-1140.
[14]张惠洁,郭卫东,屈振杰.TACE联合索拉菲尼治疗原发性肝癌的疗效观察及血清VEGF、bFGF水平的变化[J].现代肿瘤医学,2015,23(21):3164-3168.
[15]杨军英,程体娟,马建秀.平消片对荷瘤小鼠免疫功能的影响[J].中药药理与临床,2001,17(2):32-33.
[16]肖晓红,姜立伟,张荣华,等.平消片联合化疗治疗中晚期原发性肝癌的临床疗效观察[J].肿瘤药学,2012,2(3):216-219.
[17]甘雨,于新发,周成宇,等.甲胎蛋白在原发性肝癌的诊断和预后判断中的临床价值[J].海南医学,2016,27(6):891-894.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |